C 16G2

Drug Profile

C 16G2

Alternative Names: Antimicrobial peptide - C3J Therapeutics; C16G2

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator C3 Jian
  • Developer C3J Therapeutics
  • Class Antibacterials; Peptide antibiotics; Peptide fragments
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dental caries

Most Recent Events

  • 07 Jul 2017 C3 Jian initiates enrolment in a phase II trial for Dental caries (In adolescents, In adults, Prevention) in USA (NCT03196219) (Buccal strip and Varnish)
  • 21 Jun 2017 C3 Jian plans a phase II trial for Dental caries (In adolescents, In adults, Prevention) in USA (Buccal, Strip and Varnish applications) (NCT03196219)
  • 05 Apr 2017 C3 Jian completes a phase II trial in Dental caries (In adolescents, In adults, Prevention) in USA (Buccal, Strip) (NCT03052842)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top